GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (NAS:ITCI) » Definitions » Days Inventory

Intra-Cellular Therapies (Intra-Cellular Therapies) Days Inventory : 232.91 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Intra-Cellular Therapies Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Intra-Cellular Therapies's Average Total Inventories for the three months ended in Dec. 2023 was $27.3 Mil. Intra-Cellular Therapies's Cost of Goods Sold for the three months ended in Dec. 2023 was $10.7 Mil. Hence, Intra-Cellular Therapies's Days Inventory for the three months ended in Dec. 2023 was 232.91.

The historical rank and industry rank for Intra-Cellular Therapies's Days Inventory or its related term are showing as below:

ITCI' s Days Inventory Range Over the Past 10 Years
Min: 192.35   Med: 312.64   Max: 1359.07
Current: 321.87

During the past 12 years, Intra-Cellular Therapies's highest Days Inventory was 1359.07. The lowest was 192.35. And the median was 312.64.

ITCI's Days Inventory is ranked worse than
86.23% of 973 companies
in the Drug Manufacturers industry
Industry Median: 157.54 vs ITCI: 321.87

Intra-Cellular Therapies's Days Inventory declined from Dec. 2022 (319.38) to Dec. 2023 (232.91).

Inventory Turnover measures how fast the company turns over its inventory within a year. Intra-Cellular Therapies's Inventory Turnover for the three months ended in Dec. 2023 was 0.39.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Intra-Cellular Therapies's Inventory-to-Revenue for the three months ended in Dec. 2023 was 0.21.


Intra-Cellular Therapies Days Inventory Historical Data

The historical data trend for Intra-Cellular Therapies's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Days Inventory Chart

Intra-Cellular Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1,359.07 340.79 284.49 192.35

Intra-Cellular Therapies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 319.38 353.19 447.37 424.22 232.91

Competitive Comparison of Intra-Cellular Therapies's Days Inventory

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intra-Cellular Therapies's Days Inventory Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Days Inventory distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's Days Inventory falls into.



Intra-Cellular Therapies Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Intra-Cellular Therapies's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

Days Inventory (A: Dec. 2023 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (23.92 + 11.647) / 2 ) / 33.745*365
=17.7835 / 33.745*365
=192.35

Intra-Cellular Therapies's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

Days Inventory (Q: Dec. 2023 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Sep. 2023 ) + Total Inventories (Q: Dec. 2023 )) / count ) / Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=( (42.986 + 11.647) / 2 ) / 10.702*365 / 4
=27.3165 / 10.702*365 / 4
=232.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intra-Cellular Therapies  (NAS:ITCI) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Intra-Cellular Therapies's Inventory Turnover for the three months ended in Dec. 2023 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Intra-Cellular Therapies's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


Intra-Cellular Therapies Days Inventory Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Intra-Cellular Therapies (Intra-Cellular Therapies) Business Description

Traded in Other Exchanges
Address
430 East 29th Street, New York, NY, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Executives
Sharon Mates director, officer: Chairman, President & CEO C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Michael Halstead officer: SVP and General Counsel C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Suresh K. Durgam officer: Chief Medical Officer C/O INTER-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Mark Neumann officer: EVP, Chief Commercial Officer C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Lawrence J. Hineline officer: VP of Finance, CFO & Secretary C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Joel S Marcus director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Eduardo Rene Salas director C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Rory B Riggs director 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Christopher D Alafi director, 10 percent owner P.O. BOX 7338, BERKELEY CA 94707
Richard A Lerner director THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Andrew Satlin officer: EVP and Chief Medical Officer C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Kimberly E. Vanover officer: VP, Clinical Development C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Robert E Davis officer: SVP, Chief Scientific Officer 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Moshe Alafi 10 percent owner 1311 ORLEANS DRIVE, SUNNYVALE CA 94089